AI Software Platform Receives CE Mark Approval
By MedImaging International staff writers Posted on 29 May 2018 |
A broad machine vision and deep-learning software platform, which supports the assessment of multiple clinical indications, including the detection of intracranial hemorrhage (ICH), has received the CE Mark approval. The software platform named Accipio has been developed by MaxQ Artificial Intelligence (Andover, MA, USA), a global artificial intelligence (AI) healthcare company focusing on empowering confident, life-saving decision support through AI-enabled tools at the point of care.
Accurate and timely detection of ICH, commonly known as a brain bleed, is a critical step in clinical decision-making for stroke assessment and head trauma. AccipioIx, the first of multiple Accipio versions, is based on deep-learning technologies, which automatically analyzes non-contrast head computed tomography (CT) images. The AI AccipioIx algorithm is highly sensitive to the presence of ICH, identifying and prioritizing patients with ICH for the physician treating the patient. It provides a case-level signal, allowing rapid triage and prioritization of the patient and can be natively integrated into PACS systems, medical imaging hardware, or healthcare clouds. AccipioIx is now approved for commercial sale within the European Union.
"We are delighted to receive the CE Mark for AccipioIx, the first of many global regulatory approvals," said Gene Saragnese, Chairman and CEO of MaxQ-AI. "At MaxQ-AI we are developing a suite of advanced clinical decision support and workflow tools for acute healthcare physicians and their patients on a global basis. Designed to provide actionable insights, our platform leverages the power of AI, combined with the skill of the physician, leading to better patient outcomes and improved healthcare economics."
Related Links:
MaxQ Artificial Intelligence
Accurate and timely detection of ICH, commonly known as a brain bleed, is a critical step in clinical decision-making for stroke assessment and head trauma. AccipioIx, the first of multiple Accipio versions, is based on deep-learning technologies, which automatically analyzes non-contrast head computed tomography (CT) images. The AI AccipioIx algorithm is highly sensitive to the presence of ICH, identifying and prioritizing patients with ICH for the physician treating the patient. It provides a case-level signal, allowing rapid triage and prioritization of the patient and can be natively integrated into PACS systems, medical imaging hardware, or healthcare clouds. AccipioIx is now approved for commercial sale within the European Union.
"We are delighted to receive the CE Mark for AccipioIx, the first of many global regulatory approvals," said Gene Saragnese, Chairman and CEO of MaxQ-AI. "At MaxQ-AI we are developing a suite of advanced clinical decision support and workflow tools for acute healthcare physicians and their patients on a global basis. Designed to provide actionable insights, our platform leverages the power of AI, combined with the skill of the physician, leading to better patient outcomes and improved healthcare economics."
Related Links:
MaxQ Artificial Intelligence
Latest Industry News News
- Bayer and Google Partner on New AI Product for Radiologists
- Samsung and Bracco Enter Into New Diagnostic Ultrasound Technology Agreement
- IBA Acquires Radcal to Expand Medical Imaging Quality Assurance Offering
- International Societies Suggest Key Considerations for AI Radiology Tools
- Samsung's X-Ray Devices to Be Powered by Lunit AI Solutions for Advanced Chest Screening
- Canon Medical and Olympus Collaborate on Endoscopic Ultrasound Systems
- GE HealthCare Acquires AI Imaging Analysis Company MIM Software
- First Ever International Criteria Lays Foundation for Improved Diagnostic Imaging of Brain Tumors
- RSNA Unveils 10 Most Cited Radiology Studies of 2023
- RSNA 2023 Technical Exhibits to Offer Innovations in AI, 3D Printing and More
- AI Medical Imaging Products to Increase Five-Fold by 2035, Finds Study
- RSNA 2023 Technical Exhibits to Highlight Latest Medical Imaging Innovations
- AI-Powered Technologies to Aid Interpretation of X-Ray and MRI Images for Improved Disease Diagnosis
- Hologic and Bayer Partner to Improve Mammography Imaging
- Global Fixed and Mobile C-Arms Market Driven by Increasing Surgical Procedures
- Global Contrast Enhanced Ultrasound Market Driven by Demand for Early Detection of Chronic Diseases